KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Profit After Tax (2018 - 2025)

Historic Profit After Tax for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$31.3 million.

  • Esperion Therapeutics' Profit After Tax fell 612.72% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 2196.59%. This contributed to the annual value of -$51.7 million for FY2024, which is 7527.1% up from last year.
  • Esperion Therapeutics' Profit After Tax amounted to -$31.3 million in Q3 2025, which was down 612.72% from -$12.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Profit After Tax registered a high of $61.0 million during Q1 2024, and its lowest value of -$90.9 million during Q1 2021.
  • For the 5-year period, Esperion Therapeutics' Profit After Tax averaged around -$44.6 million, with its median value being -$55.1 million (2022).
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 19887.07% in 2024, then plummeted by 16629.58% in 2025.
  • Esperion Therapeutics' Profit After Tax (Quarter) stood at -$65.1 million in 2021, then grew by 14.79% to -$55.5 million in 2022, then decreased by 1.54% to -$56.3 million in 2023, then surged by 62.16% to -$21.3 million in 2024, then tumbled by 46.98% to -$31.3 million in 2025.
  • Its Profit After Tax stands at -$31.3 million for Q3 2025, versus -$12.7 million for Q2 2025 and -$40.5 million for Q1 2025.